Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rubeshan Perumal

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2026
Characterizing the dual burden of stigma in people with multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in South Africa: A mixed methods, prospective cohort studyKarl Reis, Xuan Lu, Boitumelo Seepamore, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 1, 2023
A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participantsWaasila Jassat, Caroline Mudara, Caroline Vika, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
Annals of Epidemiology|April 1, 2026
Early adherence predicts treatment outcomes and mortality in people living with HIV and multidrug-resistant tuberculosisKevin J Guzman, Rubeshan Perumal, Allison Wolf, et al.
Research Square|June 19, 2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): Study protocol for an adaptive randomized controlled trialJesse E Ross, Rubeshan Perumal, Allison Wolf, et al.
Trials|December 1, 2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trialJesse Ross, Rubeshan Perumal, Allison Wolf, et al.
The Lancet. Respiratory Medicine|March 26, 2022
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventionsKeertan Dheda, Tahlia Perumal, Harry Moultrie, et al.
The Journal of Infectious Diseases|October 16, 2024
Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical IsolatesSaranathan Rajagopalan, Amy K Rourke, Emmanuel Asare, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
BMJ Open|November 28, 2024
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TBKogieleum Naidoo, Anushka Naidoo, Alash'le G Abimiku, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2026
Characterizing the dual burden of stigma in people with multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in South Africa: A mixed methods, prospective cohort studyKarl Reis, Xuan Lu, Boitumelo Seepamore, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 1, 2023
A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participantsWaasila Jassat, Caroline Mudara, Caroline Vika, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
Annals of Epidemiology|April 1, 2026
Early adherence predicts treatment outcomes and mortality in people living with HIV and multidrug-resistant tuberculosisKevin J Guzman, Rubeshan Perumal, Allison Wolf, et al.
Research Square|June 19, 2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): Study protocol for an adaptive randomized controlled trialJesse E Ross, Rubeshan Perumal, Allison Wolf, et al.
Trials|December 1, 2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trialJesse Ross, Rubeshan Perumal, Allison Wolf, et al.
The Lancet. Respiratory Medicine|March 26, 2022
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventionsKeertan Dheda, Tahlia Perumal, Harry Moultrie, et al.
The Journal of Infectious Diseases|October 16, 2024
Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical IsolatesSaranathan Rajagopalan, Amy K Rourke, Emmanuel Asare, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
BMJ Open|November 28, 2024
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TBKogieleum Naidoo, Anushka Naidoo, Alash'le G Abimiku, et al.
Pageof 6